Bolt Acquisition Deal Drives BSX Stock Close to 52-Week High Boston Scientific stock is currently trading close to its 52-week high. In the past four trading sessions, the stock has consistently ...

Boston Scientific BSX is slated to report fourth-quarter fiscal 2024 results on Feb. 5 before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. For fourth-quarter ...

Resbiotic Nutrition Inc. ("resbiotic" or "res"), a leading provider of physician-formulated and science-backed dietary supplements, has announced a strategic distribution agreement with Grupo Columbia ...

Many people who continue with IVF feel that, if they want a child, they have no other choice. “Right now our treatment ...

Abbott’s Proclaim XR SCS system and Boston Scientific’s WaveWriter Alpha SCS system ... only FDA approved to treat DPN of the lower extremities. The cost of the spinal cord stimulation procedure ...

The medtech giant centralized operations to lower costs, brought in new leaders and added performance ... Medtronic is racing against Boston Scientific to expand in one of medtech’s hottest markets, ...

Boston Scientific Corporation develops ... such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Boston Scientific (BSX) to $115 from $95 and keeps an Overweight rating on ...

TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $115 from $110 and keeps a Buy rating on the shares. The firm expects ...

Plans to buy Bolt Medical, Inc., a developer of intravascular lithotripsy equipment for treating hardened coronary and peripheral artery disease, were announced by Boston Scientific Corporation ...